Metraipolis › archive › dc_ef275ea7dd5d
Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41303215
- DOI
- 10.3390/jcm14228181
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T11:48:11.571Z
- SHA-256 of the archived text
cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777- Stable URL of this page
https://metraipolis.com/documento/dc_ef275ea7dd5d
How to cite
Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215 — Europe PMC (en), https://europepmc.org/article/MED/41303215 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ef275ea7dd5d (Metraipolis archive dc_ef275ea7dd5d, sha256 cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777)
BibTeX
@misc{dcef275ea7dd5d,
title = {Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks — Europe PMC PMID:41303215},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41303215},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ef275ea7dd5d; sha256 cb21d671e9bbd93dbd72bf8984a234e6c13e8a40fdfea107f39cbb5f2cc39777},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303215. Agents can read the archived copy with the MCP tool read_document.